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with maternal hypertension. Early diagnosis and treatment through regular ante-
natal check-up is a key factor to prevent PIH and its complications. Interventions to 
improve maternal health through information, education and counselling of women 
of child bearing age should be implemented.
CardiovasCular disorders – Cost studies
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Objectives: Increased perioperative blood pressure (BP) variability in cardiac sur-
gery is associated with negative clinical outcomes and increased health resource 
utilization (HRU). Clevidipine, an ultrashort-acting, arterial selective calcium chan-
nel blocker reduces BP variability and may reduce HRU in this setting. The current 
model evaluates the one year budget impact of adding clevidipine to an intrave-
nous antihypertensive (IVAH) treatment mix in a sample US hospital. MethOds: 
A spreadsheet model was developed using treatment specific HRU data from a 
clevidipine clinical trial (ECLIPSE) in cardiac surgery. Treatment distribution for 
IVAH agents (clevidipine, nicardipine, nitroglycerin, and nitroprusside), case vol-
umes and comparable IVAH dosages were obtained from the Premier Hospital 
database. Unit costs for IVAH are US Wholesale Acquisition Costs (WAC). Thirty-
day event costs were from the published literature. The model inputs may be 
customized to more accurately represent a given healthcare system. Results: 
The base case assumed a sample hospital with 468 coronary artery bypass graft 
(CABG) cases and 322 heart valve (HV) cases annually. Clevidipine usage in the 
base case was minimal (0% in CABG; 1% in HV). The base case predicts a one year 
total cost of $19,045,453 with the largest proportion of costs from general ward, 
ICU and operative suite time (approx. 30%, 21%, and 20% respectively). One year 
IVAH costs totaled $93,958 or 0.5% of total costs. Increasing the proportion of cases 
receiving clevidipine to 5% for both procedures increased drug acquisition costs 
by $13,005 and decreased HRU-related costs by $48,439 for a net decrease in costs 
of $35,434 for one year. cOnclusiOns: This analysis predicts a net savings with 
an increase in clevidipine use. In this example case, a minimal increase in IVAH 
costs was offset by savings in HRU-related costs resulting from improved outcomes 
associated with reduced perioperative BP variability.
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Objectives: To construct a budget impact model (BIM) to evaluate the economic 
impact of a combination of 5% albumin and crystalloids compared to crystalloids 
alone as fluid therapy administered to patients within one day of undergoing on-
pump coronary artery bypass graft (CABG) and/or valve procedures. MethOds: 
Model parameters were obtained from clinical outcomes determined from a pro-
pensity-matched retrospective US electronic health record (EHR) database (Health 
Facts, Cerner) analysis performed to assess the differences in patient outcomes 
for those who received albumin and crystalloid solutions versus crystalloids alone 
for fluid therapy post cardiac surgery. The BIM was developed to evaluate the eco-
nomic impact of increased usage of 5% albumin for volume therapy within one 
day of undergoing on-pump cardiac surgery. The model utilizes economic costs for 
treating complications obtained from published literature and reports as well as 
data from the EHR database analysis. The BIM covers a 2-year period and presents 
annual and cumulative costs from both a total hospital and total pharmacy perspec-
tive. Results: A base case analysis for a hospital performing 100 cardiac surgeries 
per month results in a 2-yr cumulative savings of $1.32MM, assuming that 70% 
of patients require fluid resuscitation. The increased fluids cost associated with 
increased 5% albumin utilization is offset by reduced costs in hospital readmissions 
and treating fewer complications of pneumonia, acute kidney injury (AKIN stage 
III) and electrolyte abnormalities. In-hospital mortality was significantly lower in 
patients receiving 5% albumin (2.4% vs. 4.1% for crystalloids alone, p= 0.02) which is 
reported strictly as a clinical outcome within the model. cOnclusiOns: There are 
both clinical and economic advantages associated with increased utilization of 5% 
albumin for fluid therapy in patients following on-pump cardiac surgery. Hospital 
analysis of cardiac procedure outcomes and economics is particularly relevant given 
recent CMS value-based purchasing initiatives.
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Objectives: To estimate the expected cost of the pharmacological treatment 
on prevalence of arterial hypertension (AH), diabetes mellitus (DM) and dyslipi-
demia in the Chilean population, following the recent approval of Drug National 
Funds. MethOds: The drugs considered in this study and the information about it, 
were obtained through a review of clinical guideline or technical norms published by 
the health ministery of Chile. The cost was estimated using the drug consumption 
patterns from the national health survey 2009-2010 and from a vector of prices for 
every drug and their combination of uses, for both public and private health sys-
tems through the public market platform and IMS health Chile. 10.000 Montecarlo 
could be a potential link between lipid metabolism and liver diseases, which neces-
sitate further investigation.
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Objectives: Studies have shown that statins may induce diabetes in non-diabetic 
cardiovascular disease patients, as class effect. It is uncertain if any particular statin 
is more likely to have greater risk of developing diabetes; only direct and indirect 
comparison of treatment effects may clarify this uncertainty. We had previously con-
ducted a systematic literature review to estimate the relative likelihood of statin vs. 
placebo or other agents. This network meta-analysis (NMA) was conducted to rank 
the treatments according to their risk of developing diabetes. MethOds: We searched 
databases like Embase, PubMed, and Cochrane. Randomized controlled trials that 
studied one of the statins and reported incidence of diabetes as an outcome were 
considered for inclusion. Data synthesis was performed by pairwise meta-analysis 
and NMA using STATA® with routines available from www.mtm.uoi.gr. Results: 
Twelve trials were included in this review, in which 78,677 participants had been 
randomized. The follow-up ranged from two to nine years among the studies. As 
previously reported the pair-wise meta-analysis showed that statins significantly 
increased the odds of developing diabetes compared to placebo without considerable 
heterogeneity [OR 1.15; 95% CI 1.06, 1.25; p= 0.0006; I250%]. From the present NMA, the 
drug with highest odds for developing diabetes was simvastatin 80mg [OR 5.24; 95% 
credible intervals (CrI) 1.28, 21.46], followed by simvastatin 20mg [OR 4.89; 95% CrI 
1.20, 19.91], atorvastatin 80mg [OR 1.29; 95% CrI 1.00, 1.67], rosuvastatin [OR: 1.22, 95% 
CrI 1.05, 1.43] compared to placebo. Atorvastatin 10mg and pravastatin did not signifi-
cantly increase the risk of diabetes in the network meta-analysis. cOnclusiOns: 
To the best of our knowledge, this is the first study exploring this correlation. The 
NMA shows the risk of developing diabetes to be higher with simvastatin. However, 
this should be confirmed from observational studies using a large safety database.
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Objectives: To assess in a community setting the clinical characteristics, the out-
comes and the related costs of patients admitted for an acute coronary syndrome 
(ACS) or a stroke/TIA (CVD) or a peripheral artery disease (PAD). MethOds: From the 
ARNO Observatory, we carried out a record linkage analysis of discharge records for 
ACS and prescription databases, which included 2,989,512 subjects of 7 Local Health 
Authorities from Northern to Southern Italy. The accrual period lasted from January 
1 to December 31, 2011. Results: Of the 2,989,512 subjects, 6,226 (2.1‰) were hos-
pitalized for ACS, 9,939 (3.3‰) for a CVD and 1,048 (0.4‰) for PAD. Patients admitted 
for CVD were significantly older and of female gender than patients with ACS or PAD 
(age 75 ± 13 vs 71 ± 13 vs 73 ± 11, p< 0.001) (gender 50.6% vs 35.5% vs 31.9%, p < 0.001). 
In-hospital mortality rate was 6.9%, 4.6% and 1.0% (p< 0.001) respectively for CVD, 
ACS and PAD. Over the 1-year follow-up, 63.3% of the patients with ACS needed to be 
readmitted again vs 49.1 of those with CVD and 57.6% of PAD. The average yearly cost 
per patient for the ACS population was 16,897€ /year (drugs, 1,692€ ; hospitalizations, 
14,198€ ; diagnostic and outpatient visits, 1,007€ ), for the CVD 10,440€ /year (drugs, 
1,135€ ; hospitalizations, 8,745€ ; diagnostic and outpatient visits, 560€ ) and for PAD 
14,872€ /year (drugs, 1,649€ ; hospitalizations, 11,781€ ; diagnostic and outpatient vis-
its, 1,442€ ). cOnclusiOns: In a large and representative community setting, CVD 
patients have a worse in-hospital outcome than patients with ACS or PAD. However, 
the costs for the NHS were higher for patients with ACS or PAD being the main cost 
driver the need for further readmissions during the follow-up period.
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Objectives: The objective of this thesis is to study and evaluate the Dug utiliza-
tion pattern and clinical outcome in pregnancy induced hypertension in tertiary 
care hospitals. MethOds: This Retrospective observational study was carried 
out in department of obstetrics and gynecology, CKM and Vishwas hospital, S.V.R. 
Hospital, warangal. Data were collected as per inclusion and exclusion criteria 
and analyzed for drug utilization pattern of antihypertensive drugs with their 
teratogenic risk category as well as for WHO drug use indicators at initiation and 
during entire study period. Neonatal morbidity and mortality outcome was also 
assessed. Results: Out of the 165 total prescriptions studied majority were in age 
group 21-25years,illiterates and low income group. The most commonly prescribed 
antihypertensive Monotherapy was Methyldopa (35.1%) followed by Nifedipine 
(18.78%). Labetolol and Nifedipine combination was most commonly used multi 
drug regimen(9.69%). Majority drugs prescribed were from category B and C. Average 
number of drugs per prescription are five. Single drug therapy was prescribed in 
72.21 % patients.50% of the drugs are from WHO essential drug list of 18th edition. 
The most common neonatal outcome was low birth weight (84.88%), followed by 
fetal distress (9.30%), neonatal deaths(3.48%) and IUGR(2.32%).A significant correla-
tion was found between Diastolic blood pressure of mother and neonatal morbidity 
and mortality rate. cOnclusiOns: Methyldopa was the commonly prescribed anti-
hypertensive in monotherapy as well as combination for PIH. This necessitates the 
development, implementation, and evaluation of policies on the use of antihyper-
tensive drugs. The incidence of high neonatal morbidity and mortality is associated 
